Merus N.V. (MRUS), which recently secured its first FDA approval, is continuing to progress its pipeline of innovative full-length human bispecific and trispecific antibody therapeutics, known as Multiclonics. The company is also set to share updates on its clinical programs throughout this year.
The company's lead asset, Bizengri, whose chemical name is Zenocutuzumab, was granted accelerated approval by the FDA on December 4, 2024, for the treatment of NRG1 fusion-positive non-small cell lung cancer (NSCLC) and NRG1 fusion-positive pancreatic adenocarcinoma in patients who have had disease progression during or after prior systemic therapy.
For comments and feedback contact: editorial@rttnews.com
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.